Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review

Critical Reviews in Oncology/Hematology

Volumn 84, Issue 1, 2012, Pages 101-108

  Arcangeli, Stefano ^a   Scorsetti, Marta ^a   Alongi, Filippo ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Hypofractionation; Prostate cancer; Stereotactic body radiation therapy (SBRT)

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BIOCHEMICAL FAILURE FREE SURVIVAL; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; COLLIMATOR; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; LINEAR ACCELERATOR; MALE; METASTASIS POTENTIAL; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RECTUM DISEASE; REVIEW; ROBOTICS; STEREOTACTIC BODY RADIATION THERAPY; STEREOTACTIC RADIOSURGERY; TREATMENT OUTCOME; TREATMENT PLANNING; URINARY TRACT DISEASE; UROGENITAL TRACT CANCER;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOSURGERY; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84866483298     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.11.009     Document Type: Review

References (31)

1. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002, 53:1097-1105.
2. Peeters S.T.H., Heemsbergen W.D., Koper P.C.M., et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68Gy of radiotherapy with 78Gy. J Clin Oncol 2006, 24:1990-1996.
3. Brenner D.J., Martinez A.A., Edmundson G.K., Mitchell C., Thames H.D., Armour E.P. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002, 52(1):6-13.
4. Dasu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?. Clin Oncol (R Coll Radiol) 2007, 19(5):289-301.
5. Steel G.G. Basic clinical radiobiology 2003, Arnold, London.
6. Onishi H., Shirato H., Nagata Y., et al. Stereotactic body radiotherapy (SBRT) for Operable Stage I Non-Small-Cell Lung Cancer: Can SBRT Be Comparable to Surgery?. Int J Radiat Oncol Biol Phys 2010, (July). [Epub ahead of print].
7. King, Lehmann C.R., Adler J., et al. CyberKnife radiotherapy for localized prostate cancer: rationale and technical feasibility. Technol Cancer Res Treat 2003, 2:25-29.
8. Hossain S., Xia P., Huang K., et al. Dose gradient near target-normal structure interface for nonisocentric cyberknife and isocentric intensity-modulated body radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010, 78(1):58-63.
9. Chang B.K., Timmerman R.D. Stereotactic body radiation therapy: a comprehensive review. Am J Clin Oncol 2007, 30:637-644.
10. Lo S.S., Cardenes H.R., Teh B.S., et al. Stereotactic body radiation therapy for nonpulmonary primary tumors. Expert Rev Anticancer Ther 2008, 8:1939-1951.
11. Lotan Y., Stanfield J., Cho L.C., et al. Efficacy of high dose per fraction radiation for implanted human prostate cancer in a nude mouse model. J Urol 2006, 175(5):1932-1936.
12. Teh BS, Gao Y, Wang X, et al. In vitro and in vivo efficacy of ablative hypfractionation radiation/stereotactic body radiation therapy (SBRT) for human prostate cancer. In: Proceedings radiological society of North America annual meeting, abstr # SSA22-01; 2008.
13. Kupelian P.A., Willoughby T.R., Reddy C.A., et al. Hypofractionated intensity-modulated radiotherapy (70Gy at 2.5Gy per fraction) for localized prostate cancer: Cleveland clinic experience. Int J Radiat Oncol Biol Phys 2007, 68(August (5)):1424-1430.
14. Arcangeli G., Saracino B., Gomellini S., et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010, 78(September (1)):11-18.
15. Collins C.D., Lloyd-Davies R.W., Swan A.V. Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique. Clin Oncol (R Coll Radiol) 1991, 3:127-132.
16. Choi C., Cho G., Kim K., et al. Stereotactic radiation therapy of localized prostate cancer using cyberknife. Int J Radiat Oncol Biol Phys 2007, 69:S375.
17. Madsen B.L., Hsi R.A., Pham H.T., Fowler J.F., Esagui L., Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (sharp). 33.5Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007, 67(4):1099-1105.
18. Tang C.I., Loblaw D.A., Cheung P., et al. Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3. Clin Oncol (R Coll Radiol) 2008, 20(10):729-737.
19. Friedland J.L., Freeman D.E., Masterson-McGary M.E., Spellberg D.M. Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat 2009, 8(5):387-392.
20. Bolzicco G., Favretto M.S., Scremin E., et al. Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results. Technol Cancer Res Treat 2010, 9(5):473-477.
21. Katz A.J., Santoro M., Ashley R., Diblasio F., Witten M. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol 2010, 10:1.
22. King C. Stereotactic body radiotherapy for prostate cancer: current results of a phase II trial. Front Radiat Ther Oncol 2011, 43:428-437.
23. Freeman D.E., King C.R. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol 2011, 6(January):3.
24. King C.R., Brooks J.D., Gill, et al. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 2009, 73:1043-1048.
25. Fowler J.F. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 2005, 44:e265-e276.
26. Brenner D.J., Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999, 43:1095-1101.
27. Fowler J.F., Harari P.M., Leborgne F., Leborgne J.H. Acute radiation reactions in oral and pharyngeal mucosa: tolerable levels in altered fractionation schedules. Radiother Oncol 2003, 69:161-168.
28. Alongi F., Fiorino C., Cozzarini C., et al. IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol 2009, 93:207-212.
29. Lartigau E. Steretactic body radiotherapy. BMJ 2011, 343(October (7824)):24.
30. Yabroff K.R., Davis W.W., Lamont E.B., et al. Patient time costs associated with cancer care. J Natl Cancer Inst 2007, 99:14-23.
31. Sullivan R., Peppercorn J., Sikora K., et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011, 12:933-980.